Moberg Derma is Granted MSEK 4 for Limtop
11/15/2011 6:43:27 AM
STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.
comments powered by